These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17328733)

  • 21. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.
    Hernández-Torres A; García-Vázquez E; Gómez J; Canteras M; Ruiz J; Yagüe G
    Med Clin (Barc); 2012 May; 138(15):650-5. PubMed ID: 22093403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.
    Chopra T; Marchaim D; Awali RA; Krishna A; Johnson P; Tansek R; Chaudary K; Lephart P; Slim J; Hothi J; Ahmed H; Pogue JM; Zhao JJ; Kaye KS
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6270-5. PubMed ID: 24100492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
    Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
    J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
    Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
    Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.
    Abbey T; Vialichka A; Jurkovic M; Biagi M; Wenzler E
    Microbiol Spectr; 2022 Jun; 10(3):e0054222. PubMed ID: 35647655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
    Zhang TQ; Dong L; Wang ZY; Li HY
    Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
    Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
    J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
    Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
    Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: A retrospective study from a Chinese hospital.
    Zhou H; Yao Y; Zhu B; Ren D; Yang Q; Fu Y; Yu Y; Zhou J
    Medicine (Baltimore); 2019 Mar; 98(13):e14937. PubMed ID: 30921191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acinetobacter baumannii in Southern Croatia: clonal lineages, biofilm formation, and resistance patterns.
    Kaliterna V; Kaliterna M; Hrenović J; Barišić Z; Tonkić M; Goic-Barisic I
    Infect Dis (Lond); 2015; 47(12):902-7. PubMed ID: 26365683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
    Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
    Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
    Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
    Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
    Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
    Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.